Cellular impedance assays for predictive preclinical drug screening of kinase inhibitor cardiovascular toxicity

Toxicological Sciences

Volumn 135, Issue 2, 2013, Pages 402-413

  Lamore, Sarah D ^a   Kamendi, Harriet W ^a   Scott, Clay W ^a   Dragan, Yvonne P ^a   Peters, Matthew F ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Cardiotoxicity; Impedance; Kinase inhibitors

Indexed keywords

5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; 7 HYDROXYSTAUROSPORINE; ALPHA AMINO N [5,6 DIHYDRO 2 (1 METHYL 1H PYRAZOL 4 YL) 6 OXO 1H PYRROLO[4,3,2 EF][2,3]BENZODIAZEPIN 8 YL]CYCLOHEXANEACETAMIDE; COLCHICINE; MK 68; MK 8; NCS 109555; NOCODAZOLE; PACLITAXEL; PD 407824; PHOSPHOTRANSFERASE INHIBITOR; RABUSERTIB; SB 218078; SCH 900776; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CARDIOMYOCYTE IMPEDANCE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; GENE SILENCING; IMPEDANCE; IN VITRO STUDY; NONHUMAN; RAT;

CARDIOTOXICITY; IMPEDANCE; KINASE INHIBITORS.;

ANIMALS; CARDIOVASCULAR SYSTEM; DOGS; DRUG EVALUATION, PRECLINICAL; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; RATS; RATS, WISTAR;

EID: 84886552532     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kft167     Document Type: Article

References (45)

1. Altman, M. D., Bilodeau, M. T., Lim, J., Northrup, A., Stanton, M. G., and Taoka, B. M., inventors; Merck Sharp & Dohme Corp., assignee. Imidazo[1,2-a]pyridines and imadazo[1,2-b]pyridazines as MARK inhibitors. World patent WO 2010/083145 A1. July 22, 2010.
2. Anderson, V. E., Walton, M. I., Eve, P. D., Boxall, K. J., Antoni, L., Caldwell, J. J., Aherne, W., Pearl, L. H., Oliver, A. W., Collins, I., et al. (2011). CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res. 71, 463-472.
3. Borst, G. R., McLaughlin, M., Kyula, J. N., Neijenhuis, S., Khan, A., Good, J., Zaidi, S., Powell, N. G., Meier, P., Collins, I., et al. (2013). Targeted radiosensitization by the Chk1 inhibitor SAR-020106. Int. J. Radiat. Oncol. Biol. Phys. 85, 1110-1118.
4. Castillo-Carranza, D. L., Lasagna-Reeves, C. A., and Kayed, R. (2013). Tau aggregates as immunotherapeutic targets. Front. Biosci. (Schol. Ed.) 5, 426-438.
5. Cerignoli, F., Charlot, D., Whittaker, R., Ingermanson, R., Gehalot, P., Savchenko, A., Gallacher, D. J., Towart, R., Price, J. H., McDonough, P. M., et al. (2012). High throughput measurement of Ca2+ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry. J. Pharmacol. Toxicol. Methods 66, 246-256.
6. Daud, A., Springett, G. M., Mendelson, D. S., Munster, P. N., Goldman, J. W., Strosberg, J. R., Kato, G., Nesheiwat, T., Isaacs, R., and Rosen, L. S. (2010). Phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors. J. Clin. Oncol. 28, abstr 3064 (Abstract).
7. Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., and Zarrinkar, P. P. (2011). Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046-1051.
8. Dent, P., Tang, Y., Yacoub, A., Dai, Y., Fisher, P. B., and Grant, S. (2011). CHK1 inhibitors in combination chemotherapy: Thinking beyond the cell cycle. Mol. Interv. 11, 133-140.
9. Finkelstein, Y., Aks, S. E., Hutson, J. R., Juurlink, D. N., Nguyen, P., Dubnov-Raz, G., Pollak, U., Koren, G., and Bentur, Y. (2010). Colchicine poisoning: The dark side of an ancient drug. Clin. Toxicol. (Phila.) 48, 407-414.
10. Floyd, J. D., Nguyen, D. T., Lobins, R. L., Bashir, Q., Doll, D. C., and Perry, M. C. (2005). Cardiotoxicity of cancer therapy. J. Clin. Oncol. 23, 7685-7696.
11. Force, T., and Kolaja, K. L. (2011). Cardiotoxicity of kinase inhibitors: The prediction and translation of preclinical models to clinical outcomes. Nat. Rev. Drug Discov. 10, 111-126.
12. Giaever, I., and Keese, C. R. (1991). Micromotion of mammalian cells measured electrically. Proc. Natl. Acad. Sci. U.S.A. 88, 7896-7900.
13. Guo, L., Abrams, R. M., Babiarz, J. E., Cohen, J. D., Kameoka, S., Sanders, M. J., Chiao, E., and Kolaja, K. L. (2011). Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci. 123, 281-289.
14. Gutierrez-Gonzalez, A., Belda-Iniesta, C., Bargiela-Iparraguirre, J., Dominguez, G., Garcia Alfonso, P., Perona, R., and Sanchez-Perez, I. (2013). Targeting Chk2 improves gastric cancer chemotherapy by impairing DNA damage repair. Apoptosis 18, 347-360.
15. Haidle, A., Stanton, M., Altman, M., Konrad, K., Zabierek, A., Katz, J., and Jewell, J., inventors; Merck Sharp & Dohme Corp., assignee. 5,7-Dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for MARK inhibition. World patent WO 2009/152027 A1. December 17, 2009.
16. Hasinoff, B. B., and Patel, D. (2010). The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Toxicol. Appl. Pharmacol. 249, 132-139.
17. Ho, A. L., Bendell, J. C., Cleary, J. M., Schwartz, G. K., Burris, H. A., Oakes, P., Agbo, F., Barker, P. N., Senderowicz, A. M., and Shapiro, G. (2011). Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors. J. Clin. Oncol. 29, abstr 3033 (Abstract).
18. Institute of Laboratory Animal Resources (ILAR) (1996). Guide for the Care and Use of Laboratory Animals. National Research Council. National Academy Press, Washington, D.C.
19. Jonsson, M. K., Wang, Q. D., and Becker, B. (2011). Impedance-based detection of beating rhythm and proarrhythmic effects of compounds on stem cellderived cardiomyocytes. Assay Drug Dev. Technol. 9, 589-599.
20. Jordan, M. A., and Wilson, L. (2004). Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4, 253-265.
21. Kamendi, H. W., Brott, D. A., Chen, Y., Litwin, D. C., Lengel, D. J., Fonck, C., Bui, K. H., Gorko, M. A., and Bialecki, R. A. (2010). Combining radio telemetry and automated blood sampling: A novel approach for integrative pharmacology and toxicology studies. J. Pharmacol. Toxicol. Methods 62, 30-39.
22. Klein, I. (1983). Colchicine stimulates the rate of contraction of heart cells in culture. Cardiovasc. Res. 17, 459-465.
23. Kopeikina, K. J., Hyman, B. T., and Spires-Jones, T. L. (2012). Soluble forms of tau are toxic in Alzheimer's disease. Transl. Neurosci. 3, 223-233.
24. Lampidis, T. J., Kolonias, D., Savaraj, N., and Rubin, R. W. (1992). Cardiostimulatory and antiarrhythmic activity of tubulin-binding agents. Proc. Natl. Acad. Sci. U.S.A. 89, 1256-1260.
25. Lampidis, T. J., Trevorrow, K. W., and Rubin, R. W. (1986). Effects of colchicine on cardiac cell function indicate possible role for membrane surface tubulin. Exp. Cell Res. 164, 463-470.
26. Lim, J., Taoka, B. M., Lee, S., Northrup, A., Altman, M., Sloman, D., Stanton, M., and Noucti, N., inventors; Merck Sharp & Dohme Corp., assignee. Pyrazolo[1,5-A]pyrimidines as MARK inhibitors. World patent WO 2011/087999 A1. July 21, 2011.
27. Litwin, D. C., Lengel, D. J., Kamendi, H. W., and Bialecki, R. A. (2011). An integrative pharmacological approach to radio telemetry and blood sampling in pharmaceutical drug discovery and safety assessment. Biomed. Eng. Online 10, 5.
28. Ma, C. X., Janetka, J. W., and Piwnica-Worms, H. (2011). Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol. Med. 17, 88-96.
29. Mellor, H. R., Bell, A. R., Valentin, J. P., and Roberts, R. R. (2011). Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol. Sci. 120, 14-32.
30. Mery, P., Riou, B., Chemla, D., and Lecarpentier, Y. (1994). Cardiotoxicity of colchicine in the rat. Intensive Care Med. 20, 119-123.
31. Olaharski, A. J., Bitter, H., Gonzaludo, N., Kondru, R., Goldstein, D. M., Zabka, T. S., Lin, H., Singer, T., and Kolaja, K. (2010). Modeling bone marrow toxicity using kinase structural motifs and the inhibition profiles of small molecular kinase inhibitors. Toxicol. Sci. 118, 266-275.
32. Oza, V., Ashwell, S., Almeida, L., Brassil, P., Breed, J., Deng, C., Gero, T., Grondine, M., Horn, C., Ioannidis, S., et al. (2012). Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas. J. Med. Chem. 55, 5130-5142.
33. Pectasides, D., Varthalitis, J., Kostopoulou, M., Mylonakis, A., Triantaphyllis, D., Papadopoulou, M., Dimitriadis, M., and Athanassiou, A. (1998). An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer. Oncology 55, 10-15.
34. Peters, M. F., Scott, C. W., Ochalski, R., and Dragan, Y. P. (2012). Evaluation of cellular impedance measures of cardiomyocyte cultures for drug screening applications. Assay Drug Dev. Technol. 10, 525-532.
35. Pollard, C. E., Abi Gerges, N., Bridgland-Taylor, M. H., Easter, A., Hammond, T. G., and Valentin, J. P. (2010). An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br. J. Pharmacol. 159, 12-21.
36. Rowinsky, E. K., and Donehower, R. C. (1995). Paclitaxel (taxol). N. Engl. J. Med. 332, 1004-1014.
37. Schiller, J. H. (1996). High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer. Semin. Oncol. 23, 78-82.
38. Senkus, E., and Jassem, J. (2011). Cardiovascular effects of systemic cancer treatment. Cancer Treat. Rev. 37, 300-311.
39. Shah, R. R. (2006). Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 7, 889-908.
40. Sirenko, O., Crittenden, C., Callamaras, N., Hesley, J., Chen, Y. W., Funes, C., Rusyn, I., Anson, B., and Cromwell, E. F. (2013). Multiparameter in vitro assessment of compound effects on cardiomyocyte physiology using iPSC cells. J. Biomol. Screen. 18, 39-53.
41. Stevens, J. L., and Baker, T. K. (2009). The future of drug safety testing: Expanding the view and narrowing the focus. Drug Discov. Today 14, 162-167.
42. Sussman, J. S., Brozena, S. C., Skop, N., Korecka, M., and Shaw, L. M. (2004). Accidental intravenous colchicine poisoning. Ther. Drug Monit. 26, 688-692.
43. Walton, M. I., Eve, P. D., Hayes, A., Valenti, M. R., De Haven Brandon, A. K., Box, G., Hallsworth, A., Smith, E. L., Boxall, K. J., Lainchbury, M., et al. (2012). CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. Clin. Cancer Res. 18, 5650-5661.
44. Xi, B., Wang, T., Li, N., Ouyang, W., Zhang, W., Wu, J., Xu, X., Wang, X., and Abassi, Y. A. (2011). Functional cardiotoxicity profiling and screening using the xCELLigence RTCA Cardio System. J. Lab. Autom. 16, 415-421.
45. Yu, W., Polepalli, J., Wagh, D., Rajadas, J., Malenka, R., and Lu, B. (2012). A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines. Hum. Mol. Genet. 21, 1384-1390.